Complex Small Molecules Are Changing Drug R&D

WuXi AppTec details how structural complexity in protein degraders, covalent agents, and kinase programs is reshaping what integrated CRDMOs must deliver.

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.